Xceleron and Kinetigen Announce Partnership to Simplify and Empower Phase I Clinical Investigations

GERMANTOWN, Md.--(BUSINESS WIRE)--Xceleron, a leader in the design and execution of novel clinical investigations using ultra-sensitive analytical technology, has announced a partnership with Kinetigen, a clinical pharmacology consulting firm specializing in pharmacokinetics. The partnership will offer drug developers simpler and more robust early clinical investigations.

“Matching Kinetigen’s pharmacokinetic expertise with Xceleron’s AMS technology is a ‘win-win’ situation for clients seeking more robust options for analysis and interpretation of Phase I PK data.”

Non-optimized or incomplete pharmacokinetic analyses commonly result in additional expenses and lost time over the course of a development program; such problems frequently become evident during expensive proof-of-concept investigations. Thoroughly understanding the pharmacokinetics of a drug or biologic in clinical Phase I studies allows investigators to make decisions earlier. Phase I pharmacokinetic investigations must be properly designed to ensure that their results will translate into proof-of-concept and must be conducted in a cost-effective manner.

The partnership between Xceleron and Kinetigen is ideally suited to provide powerful and cost-effective investigations of Phase I drug pharmacokinetics. Kinetigen specializes in complex pharmacokinetic analyses and overall clinical pharmacology strategy. Xceleron uses Accelerator Mass Spectrometry (AMS) to gain analytical insight across a broad range of asset classes and matrix types. Together, Xceleron and Kinetigen leverage a conventional Phase I approach to expand the knowledge base and value of intellectual property before the onset of expensive late-phase clinical investigations.

“At Xceleron, we believe that technology can get life-changing drugs to people who need them, sooner and at a lower cost. This partnership with Kinetigen will help our clients do that by efficiently and cost-effectively answering critical questions earlier,” said Dr. Michael Butler, CEO of Xceleron.

“Our partnership with Xceleron is very synergistic,” said Dr. Geoffrey Banks, CEO of Kinetigen. “Matching Kinetigen’s pharmacokinetic expertise with Xceleron’s AMS technology is a ‘win-win’ situation for clients seeking more robust options for analysis and interpretation of Phase I PK data.”

About Xceleron
Xceleron provides bioanalytical AMS services for accelerated early drug development. The company pioneered human microdose and microtracer techniques using ultra-sensitive AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I and Phase II/III clinical trials. It has been providing drug development services for more than 10 years and has conducted more GLP and GCP studies than any other analytical service provider of its type. Visit Xceleron at www.xceleron.com.

About Kinetigen, Inc.
Kinetigen, Inc. is a clinical pharmacology consulting firm specializing in pharmacokinetics. Fast becoming the pharmaceutical industry’s go-to resource for pharmacokinetics, Kinetigen gives pharmaceutical companies and CROs rare access to a hands-on team of leading clinical pharmacology and pharmacokinetics professionals experienced in many different therapeutic areas. We embrace the notion that simplicity and clarity lead to good decisions by taking complex pharmacokinetic principals and making them understandable and usable for common sense drug development. Kinetigen’s flexible business structure enables us to integrate with our clients and help them maximize the potential of clinical pharmacology studies and pharmacokinetics analyses to pave the way toward marketing approval. For more information visit www.kinetigen.com.